These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29469988)

  • 21. Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas.
    Kehrer-Sawatzki H; Kluwe L; Friedrich RE; Summerer A; Schäfer E; Wahlländer U; Matthies C; Gugel I; Farschtschi S; Hagel C; Cooper DN; Mautner VF
    Hum Genet; 2018 Jul; 137(6-7):543-552. PubMed ID: 30006736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1.
    Evans DGR; Salvador H; Chang VY; Erez A; Voss SD; Schneider KW; Scott HS; Plon SE; Tabori U
    Clin Cancer Res; 2017 Jun; 23(12):e46-e53. PubMed ID: 28620004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Six cases of sporadic schwannomatosis: Topographic distribution and outcomes of peripheral nerve tumors.
    Chick G; Victor J; Hollevoet N
    Hand Surg Rehabil; 2017 Oct; 36(5):378-383. PubMed ID: 28781128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.
    Blakeley JO; Bakker A; Barker A; Clapp W; Ferner R; Fisher MJ; Giovannini M; Gutmann DH; Karajannis MA; Kissil JL; Legius E; Lloyd AC; Packer RJ; Ramesh V; Riccardi VM; Stevenson DA; Ullrich NJ; Upadhyaya M; Stemmer-Rachamimov A
    Am J Med Genet A; 2017 Jun; 173(6):1714-1721. PubMed ID: 28436162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.
    Blakeley JO; Plotkin SR
    Neuro Oncol; 2016 May; 18(5):624-38. PubMed ID: 26851632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple schwannomatosis caused by the recently described INI1 gene--molecular pathology, and implications for prognosis.
    Brennan PM; Barlow A; Geraghty A; Summers D; Fitzpatrick MM
    Br J Neurosurg; 2011 Jun; 25(3):330-2. PubMed ID: 20854059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation.
    Plotkin SR; Messiaen L; Legius E; Pancza P; Avery RA; Blakeley JO; Babovic-Vuksanovic D; Ferner R; Fisher MJ; Friedman JM; Giovannini M; Gutmann DH; Hanemann CO; Kalamarides M; Kehrer-Sawatzki H; Korf BR; Mautner VF; MacCollin M; Papi L; Rauen KA; Riccardi V; Schorry E; Smith MJ; Stemmer-Rachamimov A; Stevenson DA; Ullrich NJ; Viskochil D; Wimmer K; Yohay K; ; Huson SM; Wolkenstein P; Evans DG
    Genet Med; 2022 Sep; 24(9):1967-1977. PubMed ID: 35674741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of positron emission tomography in schwannomatosis.
    Lieber B; Han B; Allen J; Fatterpekar G; Agarwal N; Kazemi N; Zagzag D
    J Clin Neurosci; 2016 Aug; 30():138-140. PubMed ID: 26960263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis.
    Kehrer-Sawatzki H; Farschtschi S; Mautner VF; Cooper DN
    Hum Genet; 2017 Feb; 136(2):129-148. PubMed ID: 27921248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.
    Merker VL; Dai A; Radtke HB; Knight P; Jordan JT; Plotkin SR
    BMC Health Serv Res; 2018 Aug; 18(1):668. PubMed ID: 30157837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants.
    Hutter S; Piro RM; Reuss DE; Hovestadt V; Sahm F; Farschtschi S; Kehrer-Sawatzki H; Wolf S; Lichter P; von Deimling A; Schuhmann MU; Pfister SM; Jones DT; Mautner VF
    Acta Neuropathol; 2014 Sep; 128(3):449-52. PubMed ID: 25008767
    [No Abstract]   [Full Text] [Related]  

  • 32. Detection of potential lesions of Schwannomatosis visualized on
    Xia Y; Zhang J; Zhao YH; Liu HP; Wang Z; Chen Y
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):49-50. PubMed ID: 31585798
    [No Abstract]   [Full Text] [Related]  

  • 33. Long-term Follow-up and Histological Correlation of Peripheral Nervous System Alterations in Neurofibromatosis Type 2.
    Godel T; Bäumer P; Farschtschi S; Püschel K; Hofstadler B; Heiland S; Gelderblom M; Bendszus M; Hagel C; Mautner VF
    Clin Neuroradiol; 2022 Mar; 32(1):277-285. PubMed ID: 34652463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use.
    Bettegowda C; Upadhayaya M; Evans DG; Kim A; Mathios D; Hanemann CO;
    Neurology; 2021 Aug; 97(7 Suppl 1):S91-S98. PubMed ID: 34230207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurofibromatosis and Schwannomatosis.
    Plotkin SR; Wick A
    Semin Neurol; 2018 Feb; 38(1):73-85. PubMed ID: 29548054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A rare case of schwannomatosis of the extremities.
    Fodor L; Samuila S; Bodog F
    J Int Med Res; 2020 Sep; 48(9):300060520952278. PubMed ID: 32938291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Schwannomatosis: a new member of neurofibromatosis family.
    Chen SL; Liu C; Liu B; Yi CJ; Wang ZX; Rong YB; Zhu J; Ding Y; Tian GL
    Chin Med J (Engl); 2013 Jul; 126(14):2656-60. PubMed ID: 23876891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurofibromatosis type 2 (NF 2) or schwannomatosis?--Case report study and diagnostic criteria.
    Radek M; Tomasik B; Wojdyn M; Snopkowska-Wiaderna D; Błaszczyk M; Radek A
    Neurol Neurochir Pol; 2016; 50(3):219-25. PubMed ID: 27154453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas.
    Hadfield KD; Smith MJ; Urquhart JE; Wallace AJ; Bowers NL; King AT; Rutherford SA; Trump D; Newman WG; Evans DG
    Oncogene; 2010 Nov; 29(47):6216-21. PubMed ID: 20729918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiogenomics in NF2-Associated Schwannomatosis (Neurofibromatosis Type II): Exploratory Data Analysis.
    Danilov G; Makashova E; Galkin M; Karandasheva K
    Stud Health Technol Inform; 2023 Jun; 305():588-591. PubMed ID: 37387099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.